Trials / Completed
CompletedNCT04249687
Treatment of Moderate to Severe Lateral Canthal Lines
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 303 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin | neuromodulator |
| BIOLOGICAL | Placebo | placebo |
Timeline
- Start date
- 2020-02-10
- Primary completion
- 2020-09-25
- Completion
- 2021-02-10
- First posted
- 2020-01-31
- Last updated
- 2023-06-18
- Results posted
- 2023-06-18
Locations
10 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04249687. Inclusion in this directory is not an endorsement.